Clinical Trials
10 trialsNCT03570437 2022-03-02
COPELIA
University of Manchester
Phase 2 Unknown
NCT00321581 2019-11-21
AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00423332 2017-02-02
Cediranib (AZD2171, RECENTINā¢) in Metastatic or Recurrent Renal Cell Carcinoma
AstraZeneca
Phase 2 Completed
NCT00777153 2016-12-28
REGAL
AstraZeneca
Phase 3 Completed
NCT00306891 2012-11-01
Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentinā¢)
AstraZeneca
Phase 2 Completed
NCT00264004 2012-08-29
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
AstraZeneca
Phase 2 Completed
NCT00385203 2012-07-16
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
AstraZeneca
Phase 2 Completed
NCT00748891 2011-07-01
DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)
AstraZeneca
Phase 1 Completed
NCT00475956 2010-04-15
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT00503204 2009-11-25
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
AstraZeneca
Phase 1 Completed